News & Updates
Filter by Specialty:
G-CSF primary prophylaxis reduces febrile neutropenia and hospitalization, maintains chemo dose in early BC
Using a 4-day, fixed-dose schedule of filgrastim as granulocyte-colony stimulating factor (G-CSF) primary prophylaxis reduces the incidence of febrile neutropenia (FN) and associated hospitalization while maintaining the doses of adjuvant docetaxel and cyclophosphamide (TC) among Chinese women with early breast cancer (BC), a retrospective cohort study in Hong Kong has shown.
G-CSF primary prophylaxis reduces febrile neutropenia and hospitalization, maintains chemo dose in early BC
19 Jan 2023
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
Pain, discomfort persist in JIA patients despite medication use
Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.
Pain, discomfort persist in JIA patients despite medication use
18 Jan 2023
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.
Can RA patients taper MTX from targeted therapy?
18 Jan 2023
Fluvoxamine strikes out in mild-to-moderate COVID-19
Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.